Iris Noh, MD
MOHS-Micrographic Surgery · Honolulu, HINPI 1104189356
Payments from drug & device makers
Across 38 payments — averaging $32.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Revance Therapeutics, Inc.$322
- AbbVie$203
- LEO Pharma Inc.$145
- AstraZeneca$124
- Regeneron Healthcare Solutions, Inc.$72
- Lilly USA, LLC$62
- plus $304 from 11 others
What the payments were for
- Food & beverage$1,232100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Revance Therapeutics, Inc. | 5 | $322 |
| AbbVie | 6 | $203 |
| LEO Pharma Inc. | 9 | $145 |
| AstraZeneca | 1 | $124 |
| Regeneron Healthcare Solutions, Inc. | 2 | $72 |
| Lilly USA, LLC | 2 | $62 |
| Galderma Laboratories, L.p. | 2 | $51 |
| Pfizer | 2 | $43 |
| Arcutis Biotherapeutics, Inc. | 1 | $39 |
| UCB, Inc. | 1 | $28 |
| Organon | 1 | $27 |
| Globus Medical | 1 | $26 |
| Mimedx Group, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Amgen | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Biofrontera Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few mohs-micrographic surgery providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 28 | $1,959 |
| Clobetasol Propionate | 20 | $953 |
| Ketoconazole | 29 | $568 |
| Doxycycline Hyclate | 36 | $539 |
| Triamcinolone Acetonide | 42 | $390 |
| Mupirocin | 44 | $380 |
| Doxycycline Monohydrate | 13 | $252 |
| Desonide | 12 | $180 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Honolulu
- Ethan RouttHonolulu$3K
- Joseph McKinlayHonolulu$2K
- Karl VanceHonolulu$898
- Spring GoldenHonolulu$411
- Alan SongKihei$191
- Parwathi PanikerKailua Kona$149
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.